FDA Clearance Tracker · P200029-S012
TheraSphere
Last checked: Nov 20, 2026Latest source record: Apr 10, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Apr 10, 2026
Approved
Time to decision
30 days
Received Mar 11, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P200029-S012
- Device name
- TheraSphere
- Applicant
- Boston Scientific Corporation
- Applicant location
- Marborough, MA
- Received
- Mar 11, 2026
- Decided
- Apr 10, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P200029
Device type
- Device type
- Microspheres radionuclide (NAW)
- Device class
- Class III
- Specialty
- Radiology & Imaging
FDA's approval statement
As written in FDA's record.
Approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P200029/S011.
Source documents
Other decisions for Boston Scientific Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- SpaceOAR Flex System510(k)
K262151 · Decided Sep 11, 2026 · 78 days after receipt
Device type: Hydrogel Spacer (OVB) · Radiology & Imaging
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.